Insights

Innovative Therapeutics Uncommon specializes in advanced cell-based and multi-target therapies for severe lung diseases, indicating a strong potential for partnerships with healthcare providers and clinical research organizations seeking cutting-edge medical solutions.

Strong Funding Backing With $30 million in funding and revenue estimated between $10 million and $50 million, Uncommon exhibits solid financial health, making it a promising candidate for strategic investments or co-development opportunities in the biotechnology sector.

Advanced Technology Platform Utilizing polysaccharide-based delivery systems and multi-pathway cell programming, Uncommon offers scalable, efficient therapeutic platforms, creating opportunities to collaborate with pharmaceutical companies interested in novel drug delivery innovations.

Industry Connections Backed by industry leaders such as BioNTech and investors like Sam Altman, Uncommon has strong industry relationships that could facilitate introductions to larger biotech and pharmaceutical entities seeking innovative R&D collaborations.

Emerging Market Presence Uncommon's recent launch of a values-based ETF indicates a strategic expansion into innovative financial products, providing potential cross-selling opportunities in investor relations and corporate partnerships within the biotech and sustainable investment sectors.

Similar companies to Uncommon

Uncommon Tech Stack

Uncommon uses 8 technology products and services including Cloudflare Web Optimizations, Medium, Swiper, and more. Explore Uncommon's tech stack below.

Cloudflare Web Optimizations
Analytics
Medium
Blogs
Swiper
Javascript Libraries
Branch
Marketing Automation
macOS
Operating Systems & Computing Languages
SiteGround
Platform As A Service
GoDaddy
Web Hosting
Nginx
Web Servers

Media & News

Uncommon Investment Advisors Introduces Its First Equity ETF, ‘UGCE'
On Wednesday, Uncommon Giving Corporation announced the launch of its first values-based ETF on the NYSE. The Uncommon Portfolio Design Core Equity ETF (NYSE Arca: UGCE) is managed by its investment advisory affiliate, Uncommon Investment Advisors, and sub-advised by Portfolio Design Advisors, Inc. UGCE is an actively managed ETF that seeks to achieve its investment [.
Apr 21, 2021 | www.etftrends.com

Uncommon's Email Address Formats

Uncommon uses at least 2 format(s):

Uncommon Email Formats	Example	Percentage
First@highersteaks.com	John@highersteaks.com	100%
First@uncommonbio.co	John@uncommonbio.co	100%

Frequently Asked Questions

Where is Uncommon's headquarters located?

Uncommon's main headquarters is located at Newmarket Road, Cambridge, England CB5 8PB, GB. The company has employees across 3 continents, including EuropeAsiaNorth America.

What is Uncommon's stock symbol?

Uncommon is a publicly traded company; the company's stock symbol is UGCE.

What is Uncommon's official website and social media links?

Uncommon's official website is uncommonbio.co and has social profiles on LinkedIn Crunchbase.

What is Uncommon's SIC code NAICS code?

Uncommon's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Uncommon have currently?

As of October 2025, Uncommon has approximately 14 employees across 3 continents, including EuropeAsiaNorth America. Key team members include Head Of Product: K. R.Head Of Quality: A. A.Senior Operations Manager: I. R.. Explore Uncommon's employee directory with LeadIQ.

What industry does Uncommon belong to?

Uncommon operates in the Biotechnology Research industry.

What technology does Uncommon use?

Uncommon's tech stack includes Cloudflare Web OptimizationsMediumSwiperBranchmacOSSiteGroundGoDaddyNginx.

What is Uncommon's email format?

Uncommon's email format typically follows the pattern of First@highersteaks.com. Find more Uncommon email formats with LeadIQ.

When was Uncommon founded?

Uncommon was founded in 2017.

Uncommon

Biotechnology ResearchUnited Kingdom11-50 Employees

Uncommon Bio began with cell-based meat and pioneered RNA delivery innovations, which evolved into their most recent spin out which is focusing on changing medicine through multi-targeting. Their polysaccharide-based delivery platform enables multi-pathway cell programming, offering a safe, efficient and scalable alternative to multi-target therapies. The company is initially targeting severe lung diseases like idiopathic pulmonary fibrosis and is backed by industry leaders from BioNTech and top investors, including Sam Altman, Balderton, Lowercarbon, and Redalpine.

Company Overview

Headquarters: Newmarket Road, Cambridge, England CB5 8PB, GB
Website: uncommonbio.co
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: UGCE
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2017
Employees: 11-50